It’s the initial Stage II trial with cabazitaxel in gastric cancers. was a control of disease (CR + PR + SD) inn= 26 sufferers ofn= 65, corresponding to a DCR of 40.0% (95% CI 28.052.9%). In sufferers without preceding taxane use, it had been 46.2% (95% CI 25.180.8%) and in sufferers with only 1 prior therapy, DCR was 50.0% (95% CI 31.368.7%). The median general success was 4.six months (95% CI 3.16, 5.59) in the complete ITT people. In sufferers with only 1 preceding therapy, median Operating-system was 5.4 months (95% CI 2.60, 7.43) and in sufferers without taxane pretreatment, it had been 6.4 months (95% CI 1.38, 14.17). The median progression-free success period was 1.5 months (95% CI 1.32, 2.27) in the complete ITT people, 2.9 months (95% CI 0.72, 4.67) without prior taxane therapy and was 1.7 (95% CI 1.28, 3.35) months in sufferers with only 1 prior therapy median. == Conclusions == Cabazitaxel is normally active in intensely pretreated sufferers with metastatic and advanced esophagogastric junction and gastric adenocarcinoma. Efficiency leads to a vintage second-line people are much like other second-line research, therefore, beneath the limitations of the trial, (one arm, Stage II style) cabazitaxel may be an option specifically in sufferers without prior taxane therapy, in second line and even more line therapy of advanced and metastatic esophagogastric junction and gastric adenocarcinoma. Keywords:Gastric cancers, Palliative treatment, Taxane, Second series, Further series, Chemotherapy, Cabazitaxel, Stage II == History == Globally, gastric cancers is the 5th most common kind of cancers, with 952,000 new cases a complete year and the 3rd leading reason behind cancer death in both sexes worldwide. (GLOBOCAN2012). With a complete 5-year survival price of 32.4% in 2012 in Germany (GEKID2012), prognosis for the condition provides improved lately but remains to be poor slightly. The median overall success is to 812 months with first-line chemotherapy up. After mixture treatment including surgical treatments Also, greater than a fifty percent of gastric cancers patients in traditional western countries relapse (Hartgrink et al.2009). At medical diagnosis, two-thirds of sufferers have advanced cancers with regional lymph node participation or a faraway metastasis (SEER2012). In the entire case of gastric cancers that’s inoperable or includes a faraway metastasis, patients should receive palliative chemotherapy at the initial possible chance (Moehler et al.2011). This not merely expands the median success set alongside the greatest supportive treatment but also increases standard of living (Glimelius et al.1997). On first-line treatment in the palliative circumstance, a progression-free period of 67 a few months is achieved; therefore the overall success is 1011 a few months (Cunningham et al.2008; Al-Batran et al.2008b). The high occurrence, relapse price and short success after relapse or development of gastric cancers and adenocarcinoma from the esophagogastric junction (EGJ) displays an urgent dependence on a highly effective second-line and perhaps further line remedies. The outcomes of recent studies provide highest degree of proof that second-line chemotherapy can offer benefit in success and quality-of-life to chosen patients advanced after first-line chemotherapy for adenocarcinoma from the esophagogastric junction and tummy (Ford et al.2014; Hironaka et al.2013; Kang et al.2012). The initial randomized study showing a survival advantage for the second-line treatment in comparison to greatest supportive caution was conducted with the Functioning Group for Medical Oncology (AIO) in Germany. Within a multicenter potential randomized Stage III setting, the scholarly study shows a substantial survival benefit for irinotecan monotherapy vs. greatest supportive treatment in sufferers with advanced or metastatic gastric cancers (Thuss-Patience et al.2011). Docetaxel, paclitaxel, and irinotecan possess all shown efficiency and can end up being regarded as suitable for the utilization in second-line treatment for adenocarcinoma from the esophagogastric junction and tummy (Ford et al.2014) (Hironaka et al.2013; Kang et al.2012). Though taxanes are essential chemotherapeutic realtors with proven efficiency, their use is bound by resistance advancement. Data of Vrignaud et al. (2013) demonstrated that cabazitaxel, a book tubulin-binding taxane medication, is normally stronger than docetaxel in tumor versions with obtained or innate level of resistance to taxanes and other chemotherapies. The Stage III TROPIC trial confirmed the efficiency of cabazitaxel in the treating metastatic castration-resistant prostate tumor. In 2010 June, cabazitaxel, was accepted by the united states FDA for the treating metastatic castration-resistant prostate tumor that has advanced after docetaxel therapy. Treatment with cabazitaxel in the TROPIC trial demonstrated important scientific antitumor.In cases of grade 34, neutropenia persisting for a lot more than 7days and/or zero reconstitution in day 21, treatment needed to be delayed for no more than 2weeks and after an initial treatment delay, dose needed to be decreased and prophylactic G-CSF ought to be administered. preceding therapies that had received taxane therapy was 2 preceding. 80%. Sufferers received a median of two cycles of cabazitaxel. Efficiency email address details are for the ITT inhabitants. The mDCR inn= 65 sufferers was 10.8% (95% CI 4.420.9%). There is a control of disease (CR + PR + SD) inn= 26 sufferers ofn= 65, matching to a DCR of 40.0% (95% CI 28.052.9%). In sufferers without preceding taxane use, it had been 46.2% (95% CI 25.180.8%) and in sufferers with only 1 prior therapy, DCR was 50.0% (95% CI 31.368.7%). The median general success was 4.six months (95% CI 3.16, 5.59) in the complete ITT inhabitants. In sufferers with only 1 preceding therapy, median Operating-system was 5.4 months (95% CI 2.60, 7.43) and in sufferers without taxane pretreatment, it had been 6.4 months (95% CI 1.38, 14.17). The median progression-free success period was 1.5 TNF-alpha months (95% CI 1.32, 2.27) in the complete ITT inhabitants, 2.9 months (95% CI 0.72, 4.67) without prior taxane therapy and was 1.7 (95% CI 1.28, 3.35) months in sufferers with only 1 prior therapy median. == Conclusions == Cabazitaxel is certainly active in seriously pretreated sufferers with metastatic and advanced esophagogastric junction and gastric adenocarcinoma. Efficiency leads to a vintage second-line inhabitants are much like other second-line research, therefore, beneath the limitations of the trial, (one arm, Stage II style) cabazitaxel may be an option specifically in sufferers without prior taxane therapy, in second range and even more range therapy of metastatic and advanced esophagogastric junction and gastric adenocarcinoma. Keywords:Gastric tumor, Palliative treatment, Taxane, Second range, Further range, Chemotherapy, Cabazitaxel, Stage II == History == Globally, gastric tumor is the 5th most common kind of tumor, with 952,000 brand-new cases a season and the 3rd leading reason behind cancer loss of life in both sexes world-wide. (GLOBOCAN2012). With a complete 5-year JNJ-17203212 survival price of 32.4% in 2012 in Germany (GEKID2012), prognosis for the condition provides improved slightly lately but continues to be poor. The median general survival is certainly up to 812 a few months with first-line chemotherapy. Also after mixture treatment including surgical treatments, greater than a fifty percent of gastric tumor patients in traditional western countries relapse (Hartgrink et al.2009). At medical diagnosis, two-thirds of sufferers have advanced tumor with regional lymph node participation or a faraway metastasis (SEER2012). Regarding gastric tumor that’s inoperable or includes a faraway metastasis, patients should receive palliative chemotherapy at the initial possible chance (Moehler et al.2011). This not merely expands the median success set alongside the greatest supportive treatment but also boosts standard of living (Glimelius et al.1997). On first-line treatment in the palliative circumstance, a progression-free period of 67 a few months is achieved; therefore the overall success is 1011 a few months (Cunningham et al.2008; Al-Batran et al.2008b). The high occurrence, relapse price and short success after relapse or development of gastric tumor and adenocarcinoma from the esophagogastric junction (EGJ) displays an urgent dependence on a highly effective second-line and perhaps further line JNJ-17203212 remedies. The outcomes JNJ-17203212 of recent studies provide highest degree of proof that second-line chemotherapy can offer benefit in success and quality-of-life to chosen patients advanced after first-line chemotherapy for adenocarcinoma from the esophagogastric junction and abdomen (Ford et al.2014; Hironaka et al.2013; Kang et al.2012). The initial randomized study showing a survival advantage to get a second-line treatment in comparison to greatest supportive caution was conducted with the Functioning Group for Medical Oncology (AIO) in Germany. Within a multicenter potential randomized Stage III setting, the analysis displays a significant success advantage for irinotecan monotherapy vs. greatest supportive treatment in sufferers with advanced or metastatic gastric tumor (Thuss-Patience et al.2011). Docetaxel, paclitaxel, and irinotecan possess all shown efficiency and can end up being regarded as suitable for the utilization in second-line treatment for adenocarcinoma from the esophagogastric junction and abdomen (Ford et al.2014) (Hironaka et al.2013; Kang et al.2012). Though taxanes are essential chemotherapeutic agencies with proven efficiency, their use is bound by resistance advancement. Data of Vrignaud et al. (2013) demonstrated that cabazitaxel, a book tubulin-binding taxane medication, is stronger than docetaxel in tumor versions with innate or obtained level of resistance to taxanes and various other chemotherapies. The Stage III TROPIC trial confirmed the efficiency of cabazitaxel in the treating metastatic castration-resistant prostate tumor. In June 2010, cabazitaxel, was accepted by the united states FDA for the treating metastatic castration-resistant prostate tumor.A median amount of two cycles (range 06) was administered. email address details are for the ITT inhabitants. The mDCR inn= 65 sufferers was 10.8% (95% CI 4.420.9%). There is a control of disease (CR + PR + SD) inn= 26 sufferers ofn= 65, matching to a DCR of 40.0% (95% CI 28.052.9%). In sufferers without preceding taxane use, it had been 46.2% (95% CI 25.180.8%) and in sufferers with only 1 prior therapy, DCR was 50.0% (95% CI 31.368.7%). The median general success was 4.six months (95% CI 3.16, 5.59) in the complete ITT inhabitants. In sufferers with only 1 preceding therapy, median Operating-system was 5.4 months (95% CI 2.60, 7.43) and in sufferers without taxane pretreatment, it had been 6.4 months (95% CI 1.38, 14.17). The median progression-free success period was 1.5 months (95% CI 1.32, 2.27) in the complete ITT inhabitants, 2.9 months (95% CI 0.72, 4.67) without prior taxane therapy and was 1.7 (95% CI 1.28, 3.35) months in sufferers with only 1 prior therapy median. == Conclusions == Cabazitaxel is certainly active in seriously pretreated sufferers with metastatic and advanced esophagogastric junction and gastric adenocarcinoma. Efficiency leads to a vintage second-line inhabitants are much like other second-line research, therefore, under the limitations of this trial, (single arm, Phase II design) cabazitaxel might be an option especially in patients without JNJ-17203212 prior taxane therapy, in second line and even further line therapy of metastatic and advanced esophagogastric junction and gastric adenocarcinoma. Keywords:Gastric cancer, Palliative treatment, Taxane, Second line, Further line, Chemotherapy, Cabazitaxel, Phase II == Background == Globally, gastric cancer is the fifth most common type of cancer, with 952,000 new cases a year and the third leading cause of cancer death in both sexes worldwide. (GLOBOCAN2012). With an absolute 5-year survival rate of 32.4% in 2012 in Germany (GEKID2012), prognosis for the disease has improved slightly in recent years but remains poor. The median overall survival is up to 812 months with first-line chemotherapy. Even after combination treatment including surgical procedures, more than a half of gastric cancer patients in western countries relapse (Hartgrink et al.2009). At diagnosis, two-thirds of patients have advanced cancer with local lymph node involvement or a distant metastasis (SEER2012). In the case of gastric cancer that is inoperable or has a distant metastasis, patients are advised to receive palliative chemotherapy at the earliest possible opportunity (Moehler et al.2011). This not only extends the median survival compared to the best supportive care but also improves quality of life (Glimelius et al.1997). On first-line treatment in the palliative situation, a progression-free interval of 67 months is achieved; consequently the overall survival is 1011 months (Cunningham et al.2008; Al-Batran et al.2008b). The high incidence, relapse rate and short survival after relapse or progression of gastric cancer and adenocarcinoma of the esophagogastric junction (EGJ) shows an urgent need for an effective second-line and possibly further line treatments. The results of recent trials provide highest level of evidence that second-line chemotherapy can provide benefit in survival and quality-of-life to selected patients progressed after first-line chemotherapy for adenocarcinoma of the esophagogastric junction and stomach (Ford et al.2014; Hironaka et al.2013; Kang et al.2012). The first randomized study to show a survival benefit for a second-line treatment in comparison with best supportive care was conducted by the Working Group for Medical Oncology (AIO) in Germany. In a multicenter prospective randomized Phase III setting, the study shows a significant survival benefit for irinotecan monotherapy vs. best supportive care in patients with advanced or metastatic gastric cancer (Thuss-Patience et al.2011). Docetaxel, paclitaxel, and irinotecan have all shown efficacy and can be regarded as appropriate for the use in second-line treatment for adenocarcinoma of the esophagogastric junction and stomach (Ford et al.2014) (Hironaka et al.2013; Kang et al.2012). Though taxanes are important chemotherapeutic agents with proven JNJ-17203212 efficacy, their use is limited by resistance development. Data of Vrignaud et al. (2013) showed that cabazitaxel, a novel tubulin-binding taxane drug, is more potent than docetaxel in tumor models with innate or acquired resistance.It’s the initial Stage II trial with cabazitaxel in gastric cancers. was a control of disease (CR + PR + SD) inn= 26 sufferers ofn= 65, corresponding to a DCR of 40.0% (95% CI 28.052.9%). In sufferers without preceding taxane use, it had been 46.2% (95% CI 25.180.8%) Puerarin (Kakonein) and in sufferers with only 1 prior therapy, DCR was 50.0% (95% CI 31.368.7%). The median general success was 4.six months (95% CI 3.16, 5.59) in the complete ITT people. In sufferers with only 1 preceding therapy, median Operating-system was 5.4 months (95% CI 2.60, 7.43) and in sufferers without taxane pretreatment, it had been 6.4 months (95% CI 1.38, 14.17). The median progression-free success period was 1.5 months (95% CI 1.32, 2.27) in the complete ITT people, 2.9 months (95% CI 0.72, 4.67) without prior taxane therapy and was 1.7 (95% CI 1.28, 3.35) months in sufferers with only 1 prior therapy median. == Conclusions == Cabazitaxel is normally active in intensely pretreated sufferers with metastatic and advanced esophagogastric junction and gastric adenocarcinoma. Efficiency leads to a vintage second-line people are much like other second-line research, therefore, beneath the Puerarin (Kakonein) limitations of the trial, (one arm, Stage II style) cabazitaxel may be an option specifically in sufferers without prior taxane therapy, in second line and even more line therapy of advanced and metastatic esophagogastric junction and gastric adenocarcinoma. Keywords:Gastric cancers, Palliative treatment, Taxane, Second series, Further series, Chemotherapy, Cabazitaxel, Stage II == History == Globally, gastric cancers is the 5th most common kind of cancers, with 952,000 new cases a complete year and the 3rd leading reason behind cancer death in both sexes worldwide. (GLOBOCAN2012). With a complete 5-year survival price of 32.4% in 2012 in Germany (GEKID2012), prognosis for the condition provides improved lately but remains to be poor slightly. The median overall success is to 812 months with first-line chemotherapy up. After mixture treatment including surgical treatments Also, greater than a fifty percent of gastric cancers patients in traditional western countries relapse (Hartgrink et al.2009). At medical diagnosis, two-thirds of sufferers have advanced cancers with regional lymph node participation or a faraway metastasis (SEER2012). In the entire case of gastric cancers that’s inoperable or includes a faraway metastasis, patients should receive palliative chemotherapy at the initial possible chance (Moehler et al.2011). This not merely expands the median success set alongside the greatest supportive treatment but also increases standard of living (Glimelius et al.1997). On first-line treatment in the palliative circumstance, a progression-free period of 67 a few months is achieved; therefore the overall success is 1011 a few months (Cunningham et al.2008; Al-Batran et al.2008b). The high occurrence, relapse price and short success after relapse or development of gastric cancers and adenocarcinoma from the esophagogastric junction (EGJ) displays an urgent dependence on a highly effective second-line and perhaps further line remedies. The outcomes of recent studies provide highest degree of proof that second-line chemotherapy can offer benefit in success and quality-of-life to chosen patients advanced after first-line chemotherapy for adenocarcinoma from the esophagogastric junction and tummy (Ford et al.2014; Hironaka et al.2013; Kang et al.2012). The initial randomized study showing a survival advantage for the second-line treatment in comparison to greatest supportive caution was conducted with the Functioning Group for Medical Oncology (AIO) in Germany. Within a multicenter potential randomized Stage III setting, the scholarly study shows a substantial survival benefit for irinotecan monotherapy vs. greatest supportive treatment in sufferers with advanced or metastatic gastric cancers (Thuss-Patience et al.2011). Docetaxel, paclitaxel, and irinotecan possess all shown efficiency and can end up being regarded as suitable for the utilization in second-line treatment for adenocarcinoma from the esophagogastric junction and tummy (Ford et al.2014) (Hironaka et al.2013; Kang et al.2012). Though taxanes are essential chemotherapeutic realtors with proven efficiency, their use is bound by resistance advancement. Data of Vrignaud et al. (2013) demonstrated that cabazitaxel, a book tubulin-binding taxane medication, is normally stronger than docetaxel in tumor versions with obtained or innate level of resistance to taxanes and other chemotherapies. The Stage III TROPIC trial confirmed the efficiency of cabazitaxel in the treating metastatic castration-resistant prostate tumor. In 2010 June, cabazitaxel, was accepted by the united states FDA for the treating metastatic castration-resistant prostate tumor that has advanced after docetaxel therapy. Treatment with cabazitaxel in the TROPIC trial demonstrated important scientific antitumor.In cases of grade 34, neutropenia persisting for a lot more than 7days and/or zero reconstitution in day 21, treatment needed to be delayed for no more than 2weeks and after an initial treatment delay, dose needed to be decreased and prophylactic G-CSF ought to be administered. preceding therapies that had received taxane therapy was 2 preceding. 80%. Sufferers received a median of two cycles of cabazitaxel. Efficiency email address details are for the ITT inhabitants. The mDCR inn= 65 sufferers was 10.8% (95% CI 4.420.9%). There is a control of disease (CR + PR + SD) inn= 26 sufferers ofn= 65, matching to a DCR of 40.0% (95% CI 28.052.9%). In sufferers without preceding taxane use, it had been 46.2% (95% CI 25.180.8%) and in sufferers with only 1 prior therapy, DCR was 50.0% (95% CI 31.368.7%). The median general success was 4.six months (95% CI 3.16, 5.59) in the complete ITT inhabitants. In sufferers with only 1 preceding therapy, median Operating-system was 5.4 months (95% CI 2.60, 7.43) and in sufferers without taxane pretreatment, it had been 6.4 months (95% CI 1.38, 14.17). The median progression-free success period was 1.5 months (95% CI 1.32, 2.27) in the complete ITT inhabitants, 2.9 months (95% CI 0.72, 4.67) without prior taxane therapy and was 1.7 (95% CI 1.28, 3.35) months in sufferers with only 1 prior therapy median. == Conclusions == Cabazitaxel is certainly active in seriously pretreated sufferers with metastatic and advanced esophagogastric junction and gastric adenocarcinoma. Efficiency leads to a vintage second-line inhabitants are much like other second-line research, therefore, beneath the limitations of the trial, (one arm, Stage II style) cabazitaxel may be an option specifically in sufferers without prior taxane therapy, in second range and even more range therapy of metastatic and advanced esophagogastric junction and gastric adenocarcinoma. Keywords:Gastric tumor, Palliative treatment, Taxane, Second range, Further range, Chemotherapy, Cabazitaxel, Stage II == History == Globally, gastric tumor is the 5th most common kind of tumor, with 952,000 brand-new cases a season and the 3rd leading reason behind cancer loss of life in both sexes world-wide. (GLOBOCAN2012). With a complete 5-year survival price of 32.4% in 2012 in Germany (GEKID2012), prognosis for the condition provides improved slightly lately but continues to be poor. The median general survival is certainly up to 812 a few months with first-line chemotherapy. Also after mixture treatment including surgical treatments, greater than a fifty percent of gastric tumor patients in traditional western countries relapse (Hartgrink et al.2009). At medical diagnosis, two-thirds of sufferers have advanced tumor with regional lymph node participation or a faraway metastasis (SEER2012). Regarding gastric tumor that’s inoperable or includes a faraway metastasis, patients should receive palliative chemotherapy at the initial possible chance (Moehler et al.2011). This not merely expands the median success set alongside the greatest supportive treatment but also boosts standard of living (Glimelius et al.1997). On first-line treatment in the palliative circumstance, a progression-free period of 67 a few months is achieved; therefore the overall success is 1011 a few months (Cunningham et al.2008; Al-Batran et al.2008b). The high occurrence, relapse price and short success after relapse or development of gastric tumor and adenocarcinoma from the esophagogastric junction (EGJ) displays an urgent dependence on a highly effective second-line and perhaps further line remedies. The Puerarin (Kakonein) outcomes of recent studies provide highest degree of proof that second-line chemotherapy can offer benefit in success and quality-of-life to chosen patients advanced after first-line chemotherapy for adenocarcinoma from the esophagogastric junction and abdomen (Ford et al.2014; Hironaka et al.2013; Kang et al.2012). The initial randomized study showing a survival advantage to get a second-line treatment in comparison to Puerarin (Kakonein) greatest supportive caution was conducted with the Functioning Group for Medical Oncology (AIO) in Germany. Within a multicenter potential randomized Stage III setting, the analysis displays a significant success advantage for irinotecan monotherapy vs. greatest supportive treatment in sufferers with advanced or metastatic gastric tumor (Thuss-Patience et al.2011). Docetaxel, paclitaxel, and irinotecan possess all shown efficiency and can end up being regarded as suitable for the utilization in second-line treatment for adenocarcinoma from the esophagogastric junction and abdomen (Ford et al.2014) (Hironaka et al.2013; Kang et al.2012). Though taxanes are essential chemotherapeutic agencies with proven efficiency, their use is bound by resistance advancement. Data of Vrignaud et al. (2013) demonstrated that cabazitaxel, a book tubulin-binding taxane medication, is stronger than docetaxel in tumor versions with innate or obtained level of resistance to taxanes and various other chemotherapies. The Stage III TROPIC trial confirmed the efficiency of cabazitaxel in the treating metastatic castration-resistant prostate tumor. In June 2010, cabazitaxel, was accepted by the united states FDA for the treating metastatic castration-resistant prostate tumor.A median amount of two cycles (range 06) was administered. email address details are for the ITT inhabitants. The mDCR inn= 65 sufferers was 10.8% (95% CI 4.420.9%). There is a control of disease (CR + PR + SD) inn= 26 sufferers ofn= 65, matching to a DCR of 40.0% (95% CI 28.052.9%). In sufferers without preceding taxane use, it had been 46.2% (95% CI 25.180.8%) and in sufferers with only 1 prior therapy, DCR was 50.0% (95% CI 31.368.7%). The median general success was 4.six months (95% CI 3.16, 5.59) in the complete ITT inhabitants. In sufferers with only 1 preceding therapy, median Operating-system was 5.4 months (95% CI 2.60, 7.43) and in sufferers without taxane pretreatment, it had been 6.4 months (95% CI 1.38, 14.17). The median progression-free success period was 1.5 months (95% CI 1.32, 2.27) in the complete ITT inhabitants, 2.9 months (95% CI 0.72, 4.67) without prior taxane therapy and was 1.7 (95% CI 1.28, 3.35) months in sufferers with only 1 prior therapy median. == Conclusions == Cabazitaxel is certainly active in seriously pretreated sufferers with metastatic and advanced esophagogastric junction and gastric adenocarcinoma. Efficiency leads to a vintage second-line inhabitants are much like other second-line research, therefore, under the limitations of this trial, (single arm, Phase II design) cabazitaxel might be an option especially in patients without prior taxane therapy, in second line and even further line therapy of metastatic and advanced esophagogastric junction and gastric adenocarcinoma. Keywords:Gastric cancer, Palliative treatment, Taxane, Second line, Further line, Chemotherapy, Cabazitaxel, Phase II == Background == Globally, gastric cancer is the fifth most common type of cancer, with 952,000 new cases a year and the third leading cause of cancer death in both sexes worldwide. (GLOBOCAN2012). With an absolute 5-year Bmp8b survival rate of 32.4% in 2012 in Germany (GEKID2012), prognosis for the disease has improved slightly in recent years but remains poor. The median overall survival is up to 812 months with first-line chemotherapy. Even after combination treatment including surgical procedures, more than a half of gastric cancer patients in western countries relapse (Hartgrink et al.2009). At diagnosis, two-thirds of patients have advanced cancer with local lymph node involvement or a distant metastasis (SEER2012). In the case of gastric cancer that is inoperable or has a distant metastasis, patients are advised to receive palliative chemotherapy at the earliest possible opportunity (Moehler et al.2011). This not only extends the median survival compared to the best supportive care but also improves quality of life (Glimelius et al.1997). On first-line treatment in the palliative situation, a progression-free interval of 67 months is achieved; consequently the overall survival is 1011 months (Cunningham et al.2008; Al-Batran et al.2008b). The high incidence, relapse rate and short survival after relapse or progression of gastric cancer and adenocarcinoma of the esophagogastric junction (EGJ) shows an urgent need for an effective second-line and possibly further line treatments. The results of recent trials provide highest level of evidence that second-line chemotherapy can provide benefit in survival and quality-of-life to selected patients progressed after first-line chemotherapy for adenocarcinoma of the esophagogastric junction and stomach (Ford et al.2014; Hironaka et al.2013; Kang et al.2012). The first randomized study to show a survival benefit for a second-line treatment in comparison with best supportive care was conducted by the Working Group for Medical Oncology (AIO) in Germany. In a multicenter prospective randomized Phase III setting, the study shows a significant survival benefit for irinotecan monotherapy vs. best supportive care in patients with advanced or metastatic gastric cancer (Thuss-Patience et al.2011). Docetaxel, paclitaxel, and irinotecan have all shown efficacy and can be regarded as appropriate for the use in second-line treatment for adenocarcinoma of the esophagogastric junction and stomach (Ford et al.2014) (Hironaka et al.2013; Kang et al.2012). Though taxanes are important chemotherapeutic agents with proven efficacy, their use is limited by resistance development. Data of Vrignaud et al. (2013) showed that cabazitaxel, a novel tubulin-binding taxane drug, is more potent than docetaxel in tumor models with innate or acquired resistance.